Skip to main content
SpringerLink
Log in

RETRACTED ARTICLE: High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

This article was retracted on 08 October 2020

This article has been updated

Abstract

To investigate the use of high-dose therapy and autologous stem cell transplantation (ASCT) for relapsed or high-risk diffuse large B-cell lymphoma (DLBCL) between 1990 and 2007, we conducted a nationwide survey using the registry database of the Japan Society for Hematopoietic Cell Transplantation. Of the 1222 patients in the database, 576 (47%) received ASCT in first complete remission (CR1), 140 (12%) in first partial remission, 281 (23%) in sensitive relapse, 150 (12%) in resistant or sensitivity-unknown relapse, and 75 (6%) in primary refractory status. With a median follow-up of 22 months, the 2-year overall survival (OS) and progression-free survival rates were 71% and 68%, respectively. The cumulative incidences of 2-year non-relapse mortality and relapse/progression were 6% and 26%, respectively. Relapse/progression after ASCT in the rituximab era (2002–2007) was significantly lower than that in the pre-rituximab era (1990–2001; P < 0.001). Older age, male gender, poor performance status at ASCT, non-CR1 at ASCT, ASCT performed in 1990–2001, and LEED or MCEC regimen were adverse predictors of OS. Because ASCT for newly diagnosed high-risk DLBCL has not been performed recently, a registry database study to assess the impact of ASCT for relapsed or refractory DLBCL in the rituximab era is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Change history

  • 08 October 2020

    This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1007/s12185-020-03018-1

References

  1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89:3909–18.

  2. Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164:536–45.

    Article  PubMed  Google Scholar 

  3. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540–5.

    Article  CAS  PubMed  Google Scholar 

  4. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103:3684–8.

    Article  CAS  PubMed  Google Scholar 

  5. Arboe B, Halgren Olsen M, Duun-Henriksen AK, Gørløv JS, Nielsen KF, Thomsen RH, et al. Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation. Leuk Lymphoma. 2018;59:1153–62.

    Article  PubMed  Google Scholar 

  6. Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997;15:1131–7.

    CAS  PubMed  Google Scholar 

  7. Linch DC, Yung L, Smith P, Maclennan K, Jack A, Hancock B, et al. Final analysis of the UKLG LY02 trial comparing 6–8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients %3c65 years with poor prognosis histologically aggressive NHL. Br J Haematol. 2010;149:237–43.

    Article  PubMed  Google Scholar 

  8. Arranz R, Conde E, Grande C, Mateos MV, Gandarillas M, Albo C, et al. Dose-escalated CHOP and tailore intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group. Eur J Haematol. 2008;80:227–35.

    Article  PubMed  Google Scholar 

  9. Stewart DA, Bahlis N, Valentine K, Balogh A, Savoie L, Morris DG, et al. Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2006;107:4623–7.

    Article  CAS  PubMed  Google Scholar 

  10. Olivieri A, Santini G, Patti C, Chisesi T, De Souza C, Rubagotti A, et al. Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG. Ann Oncol. 2005;16:1941–8.

    Article  CAS  PubMed  Google Scholar 

  11. Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med. 2013;369:1681–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Kagami Y, Yamamoto K, Shibata T, Tobinai K, Imaizumi Y, Uchida T, et al. Randomized phase II study of R-CHOP-14 versus R-CHOP-14 followed by CHASER as induction therapy for high-dose chemotherapy (HDT), LEED, and autologous stem-cell transplantation (ASCT) in poor-risk diffuse large B-cell lymphoma (DLBCL): Japan Clinical Oncology Group (JCOG) Study (JCOG0908). Blood. 2017;130:4127 (abstract).

    Google Scholar 

  13. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184–90.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Chen YB, Hochberg EP, Feng Y, Neuberg D, Rawal B, Motyckova G, et al. Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma. 2010;51:789–96.

    Article  CAS  PubMed  Google Scholar 

  15. Fenske TS, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ, et al. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2009;15:1455–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Mounier N, Canals C, Gisselbrecht C, Cornelissen J, Foa R, Conde E, et al. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant. 2012;18:788–93.

    Article  PubMed  Google Scholar 

  17. Kamezaki K, Kikushige Y, Numata A, Miyamoto T, Takase K, Henzan H, et al. Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma. Bone Marrow Transplant. 2007;39:523–7.

    Article  CAS  PubMed  Google Scholar 

  18. Numata A, Miyamoto T, Ohno Y, Kamimura T, Kamezaki K, Tanimoto T, et al. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant. 2010;45:311–6.

    Article  CAS  PubMed  Google Scholar 

  19. Kameoka Y, Takahashi N, Ishizawa K, Kato Y, Ito J, Sasaki O, et al. Safety and feasibility of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma. Int J Hematol. 2012;96:624–30.

    Article  CAS  PubMed  Google Scholar 

  20. Kameoka Y, Akagi T, Murai K, Noji H, Kato Y, Sasaki O, et al. Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma. Int J Hematol. 2018;108:510–5.

    Article  CAS  PubMed  Google Scholar 

  21. Han LN, Zhou J, Hirose T, Imai Y, Ishiguro T, Chou T. Feasibility and efficacy of high-dose melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) chemotherapy with or without rituximab followed by autologous stem cell transplantation for aggressive and relapsed non-Hodgkin's lymphoma. Int J Hematol. 2006;84:174–81.

    Article  CAS  PubMed  Google Scholar 

  22. Nishiwaki S, Sugiura I, Miyata Y, Saito S, Sawa M, Nishida T, et al. Efficacy and safety of autologous peripheral blood stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia: a study protocol for a multicenter exploratory prospective study (Auto-Ph17 study). Medicine (Baltimore). 2017;96:e9568.

    Article  Google Scholar 

  23. Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, et al. R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY. Cancer Sci. 2018;109:2830–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Sugimoto M, Ito S, Mashima K, Umino K, Minakata D, Nakano H, et al. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan. Ann Hematol. 2016;95:1513–9.

    Article  CAS  PubMed  Google Scholar 

  25. Takaue Y, Watanabe T, Hoshi Y, Abe T, Matsunaga K, Saito S, et al. Effectiveness of high-dose MCNU therapy and hematopoietic stem cell autografts treatment of childhood acute leukemia/lymphoma with high-risk features. Cancer. 1991;67:1830–7.

    Article  CAS  PubMed  Google Scholar 

  26. Kato J, Mori T, Yokoyama K, Tsukada Y, Ueda T, Shimizu T, et al. Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma. Bone Marrow Transplant. 2011;46:923–8.

    Article  CAS  PubMed  Google Scholar 

  27. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

    Article  CAS  PubMed  Google Scholar 

  28. Gisselbrecht C. In vivo purging and relapse prevention following ASCT. Bone Marrow Transplant. 2002;29(Suppl 1):S5–9.

    Article  PubMed  Google Scholar 

  29. Ngo L, Hee SW, Lim LC, Tao M, Quek R, Yap SP, et al. Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of rituximab. Leuk Lymphoma. 2008;49:462–9.

    Article  CAS  PubMed  Google Scholar 

  30. Riihijärvi S, Taskinen M, Jerkeman M, Leppä S. Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. Eur J Haematol. 2011;86:124–8.

    Article  PubMed  Google Scholar 

  31. Carella AM, de Souza CA, Luminari S, Marcheselli L, Chiappella A, di Rocco A, et al. Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study. Leuk Lymphoma. 2013;54:53–7.

    Article  CAS  PubMed  Google Scholar 

  32. Müller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012;119:3276–84.

    Article  PubMed  Google Scholar 

  33. Pfreundschuh M, Müller C, Zeynalova S, Kuhnt E, Wiesen MH, Held G, et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood. 2014;123:640–6.

    Article  CAS  PubMed  Google Scholar 

  34. Junlén HR, Peterson S, Kimby E, Lockmer S, Lindén O, Nilsson-Ehle H, et al. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study. Leukemia. 2015;29:668–76.

    Article  PubMed  Google Scholar 

  35. Chihara D, Izutsu K, Kondo E, Sakai R, Mizuta S, Yokoyama K, et al. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study. Biol Blood Marrow Transplant. 2014;20:684–9.

    Article  CAS  PubMed  Google Scholar 

  36. Lane AA, Armand P, Feng Y, Neuberg DS, Abramson JS, Brown JR, et al. Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leuk Lymphoma. 2012;53:1130–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Caimi PF, William BM, Silva Rondon CH, Fu P, Cooper BW, Campagnaro EL, et al. Comparison of 2 carmustine-containing regimens in the rituximab era: excellent outcomes even in poor-risk patients. Biol Blood Marrow Transplant. 2015;21:1926–31.

    Article  CAS  PubMed  Google Scholar 

  38. Alessandrino EP, Bernasconi P, Colombo A, Caldera D, Martinelli G, Vitulo P, et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant. 2000;25:309–13.

    Article  CAS  PubMed  Google Scholar 

  39. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol—a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol. 2000;18:3025–30.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank all the staff of the Japanese Data Center for Hematopoietic Cell Transplantation and transplant centers in Japan for their excellent assistance and cooperation.

Funding

This work was supported by grants from the National Cancer Research and Development Fund (29-A-14, T.F.).

Author information

Authors and Affiliations

  1. Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Sung-Won Kim, Yoshitaka Asakura, Kinuko Tajima & Takahiro Fukuda

  2. Department of Hematology and Oncology, Okinawa Chubu Hospital, Uruma, Japan

    Yoshitaka Asakura

  3. Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan

    Toshiki Iwai

  4. Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan

    Hirofumi Taji

  5. Department of Hematology and Oncology, Niigata Cancer Center Hospital, Niigata, Japan

    Takaaki Chou

  6. Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, Japan

    Yasuo Morishima

  7. Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan

    Yasuo Morishima

  8. Department of Oncology and Hematology, Shimane University Hospital, Izumo, Japan

    Junji Suzumiya & Ritsuro Suzuki

  9. Hematology Division, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan

    Hisashi Sakamaki

  10. Department of HSCT Data Management and Biostatistics, Nagoya University School of Medicine, Nagoya, Japan

    Ritsuro Suzuki

Authors
  1. Sung-Won Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshitaka Asakura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kinuko Tajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toshiki Iwai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hirofumi Taji
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takaaki Chou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasuo Morishima
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Junji Suzumiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hisashi Sakamaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ritsuro Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Takahiro Fukuda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sung-Won Kim.

Ethics declarations

Conflict of interest

There are no other conflicts of interest to report.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 132 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, SW., Asakura, Y., Tajima, K. et al. RETRACTED ARTICLE: High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey. Int J Hematol 111, 256–266 (2020). https://doi.org/10.1007/s12185-019-02772-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-019-02772-1

Keywords

Search

Navigation